Table 1. Characteristics of the studies included in the meta-analysis.

Study or subgroup	Age (years) (Intervention/control)	Baseline HBV-DNA level in (log10 copies/mL)	Baseline ALT level (U/L)	Intervention/Control (n)	Treatment initiation (Gestational weeks) (Intervention/control)	Treatment discontinuation (Postpartum weeks)	Study design	Risk of bias
Han et al.23	27 (20-35)/28 (20-38) (range)	39.4 (34.1-41.6)/ 39.5 (33.5-41.3) (range)	21.45 (7.6-407.0)/ 17.1 (5.2-513.5) (range)	257/105	24.4/29	Stopped at postnatal months 1–3, while patients with CHB continued anti-HBV therapy.	Cohort	9
Hu et al.20	23.23±3.25/24.36±3.12	7.50±0.47/7.38±0.66 (log10 IU/mL)	39±16/42±20	30/30	14/28	Continued antiviral therapy	Cohort	8
Liu et al.22	27.88±3.73/28.31±3.81	7.67±0.79/7.46±0.73	46.64±58.74/28.91±38.48	24/32	2nd trimester/ 3rd trimester	Lasted until the 4th week postpartum (basic CHB treatment was continued).	Cohort	8
Pan et al.25	27.65±4.08/27.37±3.54	7.22±0.61/7.26±0.55	68.6±103.6/36.4±39.7	66/94	13-27/28-30	No description	Cohort	8
Wang et al.24	29.31±3.82/29.31±3.82	7.53±0.81/7.53±0.81	20.83±11.62/20.83±11.62	21/27	24/28	Alter delivery, 40 continue antiviral therapy, while 8 dropped out 1 month postpartum	Cohort	9
Wang et al.21 (1)	No description	6.99±1.05/7.18±1.31 (log10 IU/mL)	32.90±10.81/26.25±18.09	20/20	20/28	No description	Cohort	8
Wang et al.21 (2)	No description	6.99±1.05/7.26±1.17 (log10 IU/mL)	32.90±10.81/32.30±16.01	20/20	20/32	No description	Cohort	8
Wang et al.21 (3)	No description	6.99±1.05/6.72±1.12 (log10 IU/mL)	32.90±10.81/37.05±17.31	20/20	20/36	No description	Cohort	8
Wang et al.21 (4)	No description	7.21±1.32/7.18±1.31 (log10 IU/mL)	35.55±21.34/26.25±18.09	20/20	24/28	No description	Cohort	8
Wang et al. 21 (5)	No description	7.21±1.32/7.26±1.17 (log10 IU/mL)	35.55±21.34/32.30±16.01	20/20	24/32	No description	Cohort	8
Wang et al.21 (6)	No description	7.21±1.32/6.72±1.12 (log10 IU/mL)	35.55±21.34/37.05±17.31	20/20	24/36	No description	Cohort	8
Wang et al.18 (1)	No description	2.22±0.36/2.63±0.59 (log10 IU/mL)	33.00±10.84/27.05±17.42	20/20	20/28	No description	Cohort	8
Wang et al.18 (2)	No description	2.22±0.36/4.08±0.88 (log10 IU/mL)	33.00±10.84/32.55±15.44	20/20	20/32	No description	Cohort	8
Wang et al.18 (3)	No description	2.22±0.36/4.90±0.70 (log10 IU/mL)	33.00±10.84/37.10±17.19	20/20	20/36	No description	Cohort	8
Wang et al. 18 (4)	No description	2.47±0.48/2.63±0.59 (log10 IU/mL)	35.65±20.82/27.05±17.42	20/20	24/28	No description	Cohort	8
Wang et al.18 (5)	No description	2.47±0.48/4.08±0.88 (log10 IU/mL)	35.65±20.82/32.55±15.44	20/20	24/32	No description	Cohort	8
Wang et al.18 (6)	No description	2.47±0.48/4.90±0.70 (log10 IU/mL)	35.65±20.82/37.10±17.19	20/20	24/36	No description	Cohort	8
Yin and Wang19	29.48±5.27/28.91±6.35	7.93±0.41/7.85±0.51 (log10 IU/mL)	No description	74/149	24/28	42 days after delivery	Cohort	8
Zhou et al.17	27.43±6.72/28.07±5.26	7.52±0.63/7.43±0.72	28.28-111.25/ 26.25-108.25 (quartile)	49/64	20/28	After delivery	Cohort	8